New hope for multiple sclerosis sufferers

A drug which was developed in Cambridge and initially designed to treat a form of leukaemia has also proven effective against combating the debilitating neurological disease multiple sclerosis (MS).

The study, led by researchers from the University of Cambridge, has found that alemtuzumab not only stops MS from advancing in patients with early stage active relapsing-remitting multiple sclerosis (RRMS) but may also restore lost function caused by the disease. The findings were published today in the New England Journal of Medicine. Continue reading “New hope for multiple sclerosis sufferers”

Antibody Engineering Cuts the Collateral Damage of Cancer Drugs

Killing cancer cells, while leaving normal tissue unscathed, is almost impossible.

Nanotechnology may do the trick, but big pharmaceutical companies are far from embracing that strategy. In the meantime, highly-engineered biological molecules will fill the void.


Continue reading “Antibody Engineering Cuts the Collateral Damage of Cancer Drugs”